• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有宏观血管侵犯的肝细胞癌术后进展/超进展复发的危险因素和列线图预测模型。

Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion.

机构信息

Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Province, China.

Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, 530021, Guangxi Province, China.

出版信息

World J Surg Oncol. 2024 Nov 20;22(1):305. doi: 10.1186/s12957-024-03572-6.

DOI:10.1186/s12957-024-03572-6
PMID:39563379
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11577876/
Abstract

PURPOSE

This study aimed to develop postsurgical progression/hyperprogression recurrence (type III-IV recurrence) prediction models for hepatocellular carcinoma (HCC) patients with macroscopic vascular invasion (MaVI) and to guide treatment strategies in the accurate healthcare era.

PATIENTS AND METHODS

393 HCC patients with MaVI from two central hospitals made up the entire study population. In developmental (290 patients) and validation (103 patients) cohorts, all patients were randomized into one or the other. Two prediction models for type III-IV recurrence were developed, based on the findings of univariate and multivariate analysis in the development cohort, and multidimensional verification was carried out in both cohorts.

RESULTS

The postoperative recurrence rate of type III-IV in 393 HCC patients with MaVI was 70.9%. Young age, large tumor size (≥ 10 cm), node number, incomplete tumor capsule, postoperative complications, and high Ki67 index were the independent risk factors for relapse of type III-IV. In the development cohort, two nomograms (pre- and postoperative) had the Area Under the ROC curve (AUC) of 0.827 and 0.891, respectively. The two nomograms performed well, according to multidimensional verification methods such as clinical impact curves, decision curve analysis (DCA), and calibration curves. The validation cohort saw similar encouraging results. Both nomograms could separate patients into two distinct prognosis subgroups with ideal cutoff values of 170.3 presurgery and 175.0 postsurgery (both P < 0.05).

CONCLUSION

We constructed two novel and potentially clinically valuable models for predicting type III-IV recurrence. These two models can develop strategies for treating those suffering from HCC with MaVI owing to their strong prediction performance and availability.

摘要

目的

本研究旨在为合并宏观血管侵犯(MaVI)的肝细胞癌(HCC)患者建立术后进展/超进展复发(III-IV 型复发)预测模型,并在精准医疗时代指导治疗策略。

方法

本研究纳入了来自两家中心医院的 393 例合并 MaVI 的 HCC 患者作为研究对象。在开发(290 例)和验证(103 例)队列中,所有患者均被随机分为其中一组。基于开发队列的单因素和多因素分析结果,建立了两种 III-IV 型复发预测模型,并在两个队列中进行了多维验证。

结果

393 例合并 MaVI 的 HCC 患者的术后 III-IV 型复发率为 70.9%。年龄较小、肿瘤较大(≥10cm)、淋巴结数目、肿瘤包膜不完整、术后并发症和 Ki67 指数较高是 III-IV 型复发的独立危险因素。在开发队列中,两种列线图(术前和术后)的 AUC 分别为 0.827 和 0.891。根据临床影响曲线、决策曲线分析(DCA)和校准曲线等多维验证方法,两种列线图均表现良好。验证队列也得到了类似的令人鼓舞的结果。两种列线图均能将患者分为两个不同的预后亚组,术前截点值为 170.3,术后截点值为 175.0(均 P<0.05)。

结论

我们构建了两种用于预测 III-IV 型复发的新型、有潜在临床价值的模型。这两种模型具有较强的预测性能和可用性,可用于制定合并 MaVI 的 HCC 患者的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/4218268accac/12957_2024_3572_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/ca798a364569/12957_2024_3572_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/8d4c93baf4ba/12957_2024_3572_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/204e9c8c6ee9/12957_2024_3572_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/4218268accac/12957_2024_3572_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/ca798a364569/12957_2024_3572_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/8d4c93baf4ba/12957_2024_3572_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/204e9c8c6ee9/12957_2024_3572_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6ce/11577876/4218268accac/12957_2024_3572_Fig3_HTML.jpg

相似文献

1
Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion.伴有宏观血管侵犯的肝细胞癌术后进展/超进展复发的危险因素和列线图预测模型。
World J Surg Oncol. 2024 Nov 20;22(1):305. doi: 10.1186/s12957-024-03572-6.
2
Nomogram for predicting early recurrence of hepatocellular carcinoma with narrow resection margin.预测窄切缘肝癌早期复发的列线图。
Sci Rep. 2024 Nov 15;14(1):28103. doi: 10.1038/s41598-024-79760-x.
3
A model prediction of long-term prognosis in patients with centrally located hepatocellular carcinoma undergoing hepatectomy.中央型肝细胞癌患者行肝切除术后的长期预后模型预测。
Eur J Surg Oncol. 2018 Oct;44(10):1595-1602. doi: 10.1016/j.ejso.2018.06.009. Epub 2018 Jun 21.
4
Predictive nomograms based on gamma-glutamyl transpeptidase to prealbumin ratio for prognosis of hepatocellular carcinoma patients without microvascular invasion.基于γ-谷氨酰转肽酶与前白蛋白比值的预测列线图用于预测无微血管侵犯肝细胞癌患者的预后。
BMC Cancer. 2024 May 21;24(1):617. doi: 10.1186/s12885-024-12387-3.
5
Nomograms established for predicting microvascular invasion and early recurrence in patients with small hepatocellular carcinoma.建立预测小肝细胞癌患者微血管侵犯和早期复发的列线图。
BMC Cancer. 2024 Aug 1;24(1):929. doi: 10.1186/s12885-024-12655-2.
6
Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus.新型模型预测乙型肝炎病毒相关≤10cm 单发肝细胞癌且无门静脉癌栓患者的术后复发和总生存期。
Oncologist. 2020 Oct;25(10):e1552-e1561. doi: 10.1634/theoncologist.2019-0766. Epub 2020 Aug 6.
7
Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma.多机构验证新型模型预测巨大肝细胞癌患者预后的价值。
Int J Cancer. 2021 Jul 1;149(1):127-138. doi: 10.1002/ijc.33516. Epub 2021 Feb 27.
8
Nomograms for postsurgical extrahepatic recurrence prediction of hepatocellular carcinoma based on presurgical circulating tumor cell status and clinicopathological factors.基于术前循环肿瘤细胞状态和临床病理因素的肝癌术后肝外复发预测的列线图。
Cancer Med. 2023 Jul;12(14):15065-15078. doi: 10.1002/cam4.6178. Epub 2023 Jun 20.
9
Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy.肝癌患者手术后极早期预后列线图和结局风险分类。
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):681-689. doi: 10.1016/j.ejso.2020.10.039. Epub 2020 Oct 31.
10
Simplified nomograms based on platelet-associated models for survival prediction in Asian hepatocellular carcinoma patients after surgery.基于血小板相关模型的简化列线图用于预测亚洲肝细胞癌患者术后的生存情况。
Surg Oncol. 2019 Sep;30:131-138. doi: 10.1016/j.suronc.2019.07.008. Epub 2019 Jul 22.

引用本文的文献

1
Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma.辅助性肝动脉灌注化疗与经动脉化疗栓塞术预防肝细胞癌手术切除后早期复发的比较
J Hepatocell Carcinoma. 2025 Jul 16;12:1425-1439. doi: 10.2147/JHC.S510814. eCollection 2025.
2
Differential Infiltration of T-Cell Populations in Tumor and Liver Tissues Predicts Recurrence-Free Survival in Surgically Resected Hepatocellular Carcinoma.肿瘤和肝组织中T细胞群体的差异浸润可预测手术切除的肝细胞癌的无复发生存率。
Cancers (Basel). 2025 May 2;17(9):1548. doi: 10.3390/cancers17091548.
3

本文引用的文献

1
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).原发性肝癌诊疗指南(2022年版)
Liver Cancer. 2023 Apr 5;12(5):405-444. doi: 10.1159/000530495. eCollection 2023 Oct.
2
Enhanced recovery nursing and mental health education on postoperative recovery and mental health of laparoscopic liver resection.强化康复护理及心理健康教育对腹腔镜肝切除术后恢复及心理健康的影响
World J Gastrointest Surg. 2023 Aug 27;15(8):1728-1738. doi: 10.4240/wjgs.v15.i8.1728.
3
Treatment of hepatocellular carcinoma with macroscopic vascular invasion: A systematic review and network meta-analysis.
The role of the comprehensive complication index in the prediction of tumor-related death in transplanted patients with hepatocellular carcinoma.
综合并发症指数在预测肝细胞癌移植患者肿瘤相关死亡中的作用。
Updates Surg. 2025 Feb 10. doi: 10.1007/s13304-025-02101-8.
伴有大血管侵犯的肝细胞癌的治疗:系统评价和网络荟萃分析。
Transplant Rev (Orlando). 2023 Jul;37(3):100763. doi: 10.1016/j.trre.2023.100763. Epub 2023 Jun 5.
4
Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.术后辅助经动脉化疗栓塞治疗肝细胞癌患者的预后因素和创新的列线图模型。
Ann Med. 2023 Dec;55(1):2199219. doi: 10.1080/07853890.2023.2199219.
5
Clinical implications and biological features of a novel postoperative recurrent HCC classification: A multi-centre study.一种新型术后复发性 HCC 分类的临床意义和生物学特征:一项多中心研究。
Liver Int. 2022 Oct;42(10):2283-2298. doi: 10.1111/liv.15363. Epub 2022 Jul 25.
6
Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis.腹腔镜与开腹肝切除术治疗 BCLC 期可切除 HCC:倾向评分匹配分析。
Updates Surg. 2022 Aug;74(4):1291-1297. doi: 10.1007/s13304-022-01309-2. Epub 2022 Jun 23.
7
Prognostic Comparison Between Liver Resection and Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus: A Propensity-Score Matching Analysis.肝切除与经动脉化疗栓塞术治疗合并胆管癌栓的肝细胞癌患者的预后比较:一项倾向评分匹配分析
Front Oncol. 2022 Mar 15;12:835559. doi: 10.3389/fonc.2022.835559. eCollection 2022.
8
Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index.根据 Ki67 指数评估肝癌术后辅助经动脉化疗栓塞的疗效。
Future Oncol. 2022 Jun;18(17):2113-2125. doi: 10.2217/fon-2021-1443. Epub 2022 Mar 10.
9
Enhanced Recovery After Surgery in the Patients With Hepatocellular Carcinoma Undergoing Hemihepatectomy.肝细胞癌半肝切除术后的加速康复外科。
Surg Innov. 2022 Dec;29(6):752-759. doi: 10.1177/15533506211057628. Epub 2022 Mar 3.
10
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.肝切除术与索拉非尼治疗晚期非转移性肝细胞癌的真实世界多中心加权比较
Ann Surg. 2022 Apr 1;275(4):743-752. doi: 10.1097/SLA.0000000000005373.